NRx Pharmaceuticals, Inc.
NRXP
NASDAQ·Healthcare·Biotechnology·Mkt cap $60.3M
$3.49
▲ +1.75%
P/E
-4.70
Mkt Cap
$60.3M
52-Wk Range
$1.62–$5.06
52-Week Range
$1.62 - $5.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 22.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel drug candidates addressing high-mortality unmet medical needs
- Proprietary formulations with potential for rapid clinical advancement
- Focused pipeline targeting underserved psychiatric and pulmonary markets
- Clinical trial data demonstrating therapeutic efficacy in critical patient populations
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Strong growth ahead
FDA regulatory approvals and commercialization of ZYESAMI and NRX candidates
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-15.7% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NRXP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 14, 2026
Reported EPS of -$0.18 vs -$0.11 consensus (-68.7% surprise). Revenue of $1.1M vs $1.3M expected (-17.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-68.7%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$242.0K
$983.0K
$1.1M
$1.1M
Margins · last 8Q
Gross
0.0%
Profit
-1500.5%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How NRXP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.